Health & Fitness
Mon, June 25, 2012
REDWOOD CITY, Calif.--([ BUSINESS WIRE ])--Codexis, Inc. (NASDAQ:CDXS), a developer of industrial enzymes to enable the cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical intermediates, today announced that Brian Dowd has resigned as interim Chief Financial Officer, Vice President and Controller, effective June 28, 2012, in order to accept a position at a private technology company. John J. Nicols, the companyas newly appointed President and Chief Executive Officer, and the Board of Directors will continue Codexisa ongoing search for a permanent CFO.
"We are grateful for his leadership, and we all wish Brian the best in his new position."
aWe thank Brian for his contributions to Codexis,a said Mr. Nicols. aWe are grateful for his leadership, and we all wish Brian the best in his new position.a
About Codexis, Inc.
Codexis, Inc. is a developer of industrial enzymes to enable the cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical intermediates. Codexis' product lines include CodeXymea" Cellulase Enzymes and CodeXola" Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see [ www.codexis.com ].
